NCT07260877RecruitingPhase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
Ventus Therapeutics U.S., Inc.33 sites in 8 countries24 target enrollmentStarted: December 3, 2025Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 24
- Locations
- 33
- Primary Endpoint
- Evaluate the effect of VENT-03 on the interferon gene signature in the skin
Study Overview
Brief Summary
The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus erythematosus (SLE). Another goal is to learn about the safety of VENT-03 and how it is processed by the body. The main questions it aims to answer are:
- Does VENT-03 affect the activity and severity of CLE?
- What side effects do participants have when taking VENT-03?
Researchers will compare VENT-03 to a placebo (a look-alike substance that contains no drug) to see if VENT-03 works to treat patients with CLE.
Participants will:
- Take VENT-03 or a placebo for 4 weeks, then all participants will switch to VENT-03 for another 8 weeks;
- Visit the clinic once a month for checkups and tests.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description
Sponsor
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Cutaneous lupus:
- •CLASI-A score ≥8;
- •At least 1 active discoid lupus erythematosus (DLE) lesion, OR at least 1 active subacute CLE lesion
- •If participant has previous SLE diagnosis:
- •Positive antinuclear antibody test at Screening by immunofluorescent assay at the central laboratory with titer ≥ 1:80;
- •Meets the American College of Rheumatology/ European Alliance of Associations for Rheumatology 2019 criteria for SLE; and
- •Currently receiving at least one of the specified SLE medication treatments, at stable doses.
Exclusion Criteria
- •Meet protocol-specified infection or lab criteria; any other laboratory test results that, in the investigator's opinion, might place participant at unacceptable risk for participating in this study;
- •Moderate or severe liver impairment as classified by the Child-Pugh criteria (categories B and C);
- •Has drug-induced lupus, rather than 'idiopathic' lupus;
- •History of, or current, inflammatory joint or skin disease other than SLE and cutaneous lupus;
- •Diagnosis of select potentially confounding autoimmune disorders
- •Active severe or unstable neuropsychiatric SLE;
- •Hospitalization for a severe lupus flare in the past 3 months, or active severe SLE-driven disease, including lupus nephritis, for which in the opinion of the PI the protocol-specified SOC is insufficient;
- •History of or current diagnosis of anti-phospholipid syndrome;
- •History of any non-lupus disease that has required treatment with oral or parenteral corticosteroids for more than a total of 2 weeks within the last 24 weeks prior to Day 1;
- •Meets protocol specified medical history of infectious diseases and infections and/or opportunistic infection requiring hospitalization or parenteral antimicrobial treatment within specified timeframes;
- •Cancer screening results suspicious of malignancy or history of cancer within time specified with exceptions for curative therapy for squamous or basil cell carcinoma and cervical cancer in situ; and
- •Meets protocol specified exclusions related to concomitant medications.
Arms & Interventions
Placebo
Placebo Comparator
Placebo
Intervention: Placebo (Drug)
VENT-03
Experimental
VENT-03
Intervention: VENT-03 (Drug)
Outcomes
Primary Outcomes
Evaluate the effect of VENT-03 on the interferon gene signature in the skin
Time Frame: Baseline to End of Double-Blind Treatment (up to Day 28)
Percent change from baseline in interferon gene signature in the skin at Day 28
Secondary Outcomes
- Change from Baseline in Myxovirus-Resistant Protein A (MXA) Immunostaining in Skin Biopsy(Baseline to End of Treatment (up to Day 84))
- Number of participants with at least one Treatment Emergent Adverse Event (TEAE) and/or Serious Adverse Event (SAE)(Baseline to End of Treatment (up to Day 84))
- Number of participants with Moderate or Severe Treatment Emergent Adverse Events (TEAEs)(Baseline to End of Treatment (up to Day 84))
- Percentage of Participants with ≥ 1 Treatment Emergent Adverse Event (AE) leading to Treatment Discontinuation(Baseline to End of Treatment (up to Day 84))
- Cmax: Maximum Observed Plasma Concentration for VENT-03(Day 1 pre-dose and at multiple time points (up to 6 hours) post-dose; Day 28 pre-dose and post-dose; Day 56 and Day 84 pre-dose)
- AUClast: Area Under the Plasma Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration for VENT-03(Day 1 pre-dose and at multiple time points (up to 6 hours) post-dose; Day 28 pre-dose and post-dose; Day 56 and Day 84 pre-dose)
- Evaluate the effect of VENT-03 on CLE disease severity(Baseline to End of Double-Blind Treatment (up to Day 28))
- Change from Baseline in Myxovirus-Resistant Protein A (MXA) Immunostaining in Skin Biopsy(Baseline to End of Treatment (up to Day 84))
- Evaluate effect of VENT-03 on CLE disease severity(Baseline to End of Double-Blind Treatment (up to Day 28))
- Number of participants with at least one Treatment Emergent Adverse Event (TEAE) and/or Serious Adverse Event (SAE)(Baseline to End of Treatment (up to Day 84))
- Number of participants with Moderate or Severe Treatment Emergent Adverse Events (TEAEs)(Baseline to End of Treatment (up to Day 84))
- Percentage of Participants with ≥ 1 Treatment Emergent Adverse Event (AE) leading to Treatment Discontinuation(Baseline to End of Treatment (up to Day 84))
- Cmax: Maximum Observed Plasma Concentration for VENT-03(Day 1 pre-dose and at multiple time points (up to 6 hours) post-dose; Day 28 pre-dose and post-dose; Day 56 and Day 84 pre-dose)
- AUClast: Area Under the Plasma Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration for VENT-03(Day 1 pre-dose and at multiple time points (up to 6 hours) post-dose; Day 28 pre-dose and post-dose; Day 56 and Day 84 pre-dose)
Investigators
Study Sites (33)
Loading locations...
Similar Trials
Recruiting
Phase 2
Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 InhibitorsBreast CancerNCT07258108Sun Yat-sen University35
Recruiting
Phase 2
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell LymphomaMantle Cell LymphomaNCT07261163Institute of Hematology & Blood Diseases Hospital, China37
Recruiting
Phase 2
Topical Ketotifen 0.25% for Secondary VestibulodyniaNCT07257029Center for Vulvovaginal Disorders54
Active, not recruiting
Not Applicable
A clinical study to explore the therapeutic effects of different doses ofthe new drug veltuzumab, a drug of biologic origin, and placebo, inpatients with rheumatoid arthritis.Rheumatoid ArthritisEUCTR2010-022378-15-ESycomed GmbH300
Active, not recruiting
Not Applicable
VELVET (Veltuzumab various doses exploratory trial), a randomized, double blind, placebo controlled, multicentre, multinational phase II dose range finding trial in subjects with moderate to severe rheumatoid arthritis insufficiently controlled with either methotrexate alone or methotrexate plus anti-tumour necrosis factor biological treatment, comparing 3 different subcutaneous dosages of anti-CD20 monoclonal antibody veltuzumab to placebo as an add-on therapy to methotrexate. - VELVETMedDRA version: 12.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2010-022378-15-HUycomed GmbH300